Although inactivation or loss of Smad4 occurs in the majority of pancreatic cancer, targeting Smad4 or other Smads as treatment of PDAC may not be successful due to presence of the Smad-independent TGF-β signaling pathway. Here, TGFB1 is linked to familial pancreatic carcinoma.